Bristol Myers Squibb (CELG-RI) Income from Non-Controlling Interests (2009 - 2026)

Bristol Myers Squibb (CELG-RI) reported Income from Non-Controlling Interests of $1.0 million for Q1 2026, down 83.33% year-over-year from $6.0 million in Q1 2025, and up 200.0% quarter-over-quarter from -$1.0 million in Q4 2025.

Bristol Myers Squibb (CELG-RI) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends

Bristol Myers Squibb (CELG-RI) has 18 years of Income from Non-Controlling Interests data on file, last reported at $1.0 million in Q1 2026.

  • Income from Non-Controlling Interests for Q1 2026 came in at $1.0 million, down 83.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.0 million (down 122.22% YoY), and the FY2025 annual result was $2.0 million, down 86.67% from the prior year.
  • Income from Non-Controlling Interests grew to $1.0 million in Q1 2026 per CELG-RI's latest filing, from -$1.0 million in the prior quarter.
  • Over five years, Income from Non-Controlling Interests peaked at $8.0 million in Q2 2022 and troughed at -$6.0 million in Q3 2025.
  • A 5-year average of $3.1 million and a median of $4.0 million in 2023 frame the typical range for Income from Non-Controlling Interests.
  • The sharpest annual moves came in 2023 and 2025: Income from Non-Controlling Interests jumped 200.0% in 2023, then sank 250.0% in 2025.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at $3.0 million in 2022, then jumped by 100.0% to $6.0 million in 2023, then tumbled by 33.33% to $4.0 million in 2024, then slumped by 125.0% to -$1.0 million in 2025, then jumped by 200.0% to $1.0 million in 2026.
  • Business Quant data shows CELG-RI's Income from Non-Controlling Interests at $1.0 million in Q1 2026, -$1.0 million in Q4 2025, and -$6.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 2.48 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn -
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn -
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 2.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -3.00 Mn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn -
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn -
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 8.00 Mn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 1.00 Mn
10 Bristol Myers Squibb - - 8.07 Bn 1.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.00 Mn
Dec 31, 2025 -1.00 Mn
Sep 30, 2025 -6.00 Mn
Jun 30, 2025 2.00 Mn
Mar 31, 2025 6.00 Mn
Dec 31, 2024 4.00 Mn
Sep 30, 2024 4.00 Mn
Jun 30, 2024 4.00 Mn
Mar 31, 2024 3.00 Mn
Sep 30, 2023 6.00 Mn
Jun 30, 2023 4.00 Mn
Mar 31, 2023 5.00 Mn
Dec 31, 2022 3.00 Mn
Sep 30, 2022 2.00 Mn
Jun 30, 2022 8.00 Mn
Mar 31, 2022 5.00 Mn
Sep 30, 2021 6.00 Mn
Jun 30, 2021 6.00 Mn
Mar 31, 2021 8.00 Mn
Sep 30, 2020 6.00 Mn